跳至主要内容
临床试验/NCT01490645
NCT01490645已完成不适用

ProAcor: Prospective Structured Care In Acute Coronary Syndrome Registry

AstraZeneca1 个研究点 分布在 1 个国家目标入组 1,006 人开始时间: 2011年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
1,006
试验地点
1
主要终点
The number of patients who can be guided through the structured outpatient care program offered within this project by assessing the percentage of patients with diagnosis of Acute Coronary Syndrome (ACS) following the care program.

研究概览

简要总结

The purpose of the study is to analyse patient's acceptance and willingness to participate in a Structured Care Program (SCP) over 12 months following hospital discharge after Acute Coronary Syndrome (ACS) index event.

详细描述

ProAcor: Prospective Structured Care In Acute Coronary Syndrome Registry

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients hospitalized because of ACS (ST segment elevation myocardial infarction (STEMI)), non-ST elevation myocardial infarction (NSTEMI) Unstable Angina (UA)) and planned to be discharged alive soon.

排除标准

  • Myocardial infarction (UA, STEMI and NSTEMI) precipitated by or as a complication of surgery, trauma, or Gastrointestinal Bleeding or post- percutaneous coronary intervention (PCI).
  • Myocardial infarction (UA, STEMI and NSTEMI) occurring in patients already hospitalized for other reasons.
  • Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, known diagnosed psychiatric illness

结局指标

主要结局

The number of patients who can be guided through the structured outpatient care program offered within this project by assessing the percentage of patients with diagnosis of Acute Coronary Syndrome (ACS) following the care program.

时间窗: up to 24 months

after collecting all Case Record Form

次要结局

  • Description of changes in quality of life (QoL) during the period of 12 months.(up to 12 months)
  • Description of adherence to guideline conform treatment and patients' compliance with the lifestyle changes recommended by the physician (e.g. body weight, blood pressure, Low Density Lipoprotein (LDL)).(up to 12 months)
  • Description of newly occurred cardiac symptoms (e.g. troponin, LVH), as determined by routine examinations by the cardiologists, which cause a declining state of health.(up to 12 months)
  • Frequency of changes in ambulant treatment according to the acceptance of the program.(up to 12 months)
  • Description of reasons of premature withdrawal from the program.(up to 12 months)
  • Description of acceptance of the program between subgroups (e.g. gender, risk scores, types of ACS, multimorbidity, medical treatment, therapy).(up to 12 months)
  • Description of patients's needs in long term care of ACS.(up to 12 months)
  • Frequency of newly occurred symptomatic acute cardiac events according to the acceptance of the program.(up to 12 months)
  • Frequency of resource use according to the acceptance of the program.(up to 12 months)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验